Since primary tumor cells from patients have been used as a model for assessment of drug response for individual patients, this study aims to evaluate the reliability of such a model in colorectal cancer (CRC) in predicting the response of tumor tissues through comparison of their expression profiles.
Establishment of primary cultures from tissues obtained surgically from CRC patients allowed us to study the gene expression differences between normal and tumor tissues as well as primary cultures derived from the tumor mass. The tissues comparison highlights the molecular characteristics of tumors, while the comparison between primary tumor cells versus normal and tumor tissues allowed us to identify alterations associated with the establishment of culture. Genes-drug association analyses allowed us to fine-tune our expectations while using primary culture as a model for drug assessment.
Comparison between tumor cultures and original tissues through functional analyses showed the deregulations caused by culture establishment. Investigating the impact of such changes in genes-drug associations to identify the potential alterations in drug response, we found that primary cultures may have increased susceptibility toward paclitaxel, but reduced susceptibility toward analogues of fluorouracil compared with original tumors.
Response of primary tumor cells toward different drugs is not linearly associated to tumor tissues. Our results highlight the importance to account for the discrepancy in responses between the primary tumor cells and original counterparts in order to provide clinicians with important insights to improve selection of drugs for individual patients based on in vitro assays.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Alberts DS, Samon SE, Chen HS, Surwit EA, Soehnlen B, Young L et al (1980) In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2(8190):340–342
Arango D, Wilson A, Shi Q, Corner G, Arañes M, Nicholas C et al (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91(11):1931–1946
Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R et al (2005) Gene-expression profiling predicts recurrence in Dukes’ C colorectal cancer. Gastroenterology 129(3):874–884
Bainard L, Bainard J, Newmaster S, Klironomos J (2011) Mycorrhizal symbiosis stimulates endoreduplication in angiosperms. Plant Cell Environ 34(9):1577–1585
Barrier A, Lemoine A, Boelle P, Tse C, Brault D, Chiappini F et al (2005a) Colon cancer prognosis prediction by gene expression profiling. Oncogene 24(40):6155–6164
Barrier A, Boelle PY, Lemoine A, Tse C, Brault D, Chiappini F et al (2005b) Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 48(12):2238–2248
Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24(29):4685–4691
Barrier A, Roser F, Boëlle PY, Franc B, Tse C, Brault D et al (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26(18):2642–2648
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238–1242
Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA et al (2005) Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study. Ann Oncol 16(Suppl 4):iv50–iv55
Brouquet A, Taleb P, Lot AS, Beauchet A, Julie C, Prevost G et al (2011) A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity. J Surg Res 166(2):247–254
Burgering BMT (2008) A brief introduction to FOXOlogy. Oncogene 27(16):2258–2262
Cardoso J, Boer J, Morreau H, Fodde R (2007) Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 1775(1):103–137
Chen J, Aronow B, Jegga A (2009a) Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics 10:73
Chen J, Bardes EE, Aronow BJ, Jegga AG (2009b) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37(Web Server issue):W305–W311
Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25(6):534–555
Collins FS, Green ED, Guttmacher AE, US National Human Genome Research Institute (2003) A vision for the future of genomics research. Nature 422(6934):835–847
Cree IA, Glaysher S, Harvey AL (2010) Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10(4):375–379
Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, Rosenstein M et al (2011) The comparative toxicogenomics database: update 2011. Nucleic Acids Res 39(Database issue):D1067–D1072
Del R, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P et al (2007) Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 25(7):773–780
Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A et al (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23(15):3526–3535
Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA et al (2006) Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anticancer Drugs 17(8):913–919
Fruehauf J, Alberts D (2003) Assay-assisted treatment selection for women with breast or ovarian cancer. Recent Results Cancer Res 161:126–145
Fruehauf JP, Alberts DS (2005) In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 23(15):3641–3643 author reply 3646
Fu Z, Tindall DJ (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27(16):2312–2319
Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47–76
Jeppesen P (2000) Immunofluorescence in cytogenetic analysis: method and applications. Genet Mol Bio 23:1003–1014
Khambata-Ford S, Garrett C, Meropol N, Basik M, Harbison C, Wu S et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230–3237
Kulendran M, Stebbing JF, Marks CG, Rockall TA (2011) Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers 3(2):1622–1638
La Farina M, Maturi N, Stira S, Russo A, Bazan V, Albanese I et al (1998) Direct identification of each specific mutation in codon 12 and 13 of ci-ki-ras2 by SSCP analysis. Biochem Biophys Res Commun 246(3):813–815
Lander ES (1996) The new genomics: global views of biology. Science 274(5287):536–539
Lee J, Lee I, Han B, Park J, Jang J, Park C et al (2011) Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103(8):674–688
Lippert TH, Ruoff HJ, Volm M (2011) Current status of methods to assess cancer drug resistance. Int J Med Sci 8(3):245–253
Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML et al (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189(5):1301–1307
Luca T, Privitera G, Lo Monaco M, Prezzavento C, Castorina S (2007) Validation study of a cell culture model of colorectal cancer. Ital J Anat Embryol 112(2):81–92
Mariadason J, Arango D, Shi Q, Wilson A, Corner G, Nicholas C et al (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63(24):8791–8812
Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P et al (2010) Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol 2010:861341
Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K et al (1990) Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res 50(22):7166–7173
Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M (1995) Familial polyposis: recent advances. Crit Rev Oncol Hematol 19(1):1–31
Moyer A, Sun Z, Batzler A, Li L, Schaid D, Yang P et al (2010) Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 19(3):811–821
Muleris M, Salmon R, Dutrillaux B (1990) Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet 46(2):143–156
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446(7137):758–764
Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191):110–114
Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G et al (2009) Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 35(3):201–209
Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y et al (2008) Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 61(4):587–594
Penland SK, Goldberg RM (2004) Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park) 18(6):715–722 727, discussion 727
Pezo R, Gandhi S, Shirley L, Pestell R, Augenlicht L, Singer R et al (2008) Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. Cancer Res 68(13):4977–4982
Puig P, Guilly M, Bouchot A, Droin N, Cathelin D, Bouyer F et al (2008) Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 32(9):1031–1043
Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34(2):374–378
Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR et al (2004) American society of clinical oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22(17):3631–3638
Schwerer MJ, Hemmer J, Kraft K, Maier H, Möller P, Barth TFE et al (2003) Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma. Virchows Arch 443(1):98–103
Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y et al (2005) Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol 27(2):371–376
Stein WD, Litman T, Fojo T, Bates SE (2004) A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 64(8):2805–2816
Szakács G, Gottesman MM (2004) Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. Mol Interv 4(6):323–325
Varesco L, Gismondi V, James R, Robertson M, Grammatico P, Groden J et al (1993) Identification of APC gene mutations in Italian adenomatous polyposis coli patients by PCR-SSCP analysis. Am J Hum Genet 52(2):280–285
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893–898
Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW et al (2005) Colorectal cancer. Lancet 365(9454):153–165
Williams B, Bateman J, Novikov N, Wu C (2007) Disruption of topoisomerase II perturbs pairing in drosophila cell culture. Genetics 177(1):31–46
Wilson M, Brosens J, Schwenen H, Lam E (2011) FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets 12(9):1256–1266
The authors show gratitude to Dashayini Mahalingam for technical assistance and proof reading. We express thanks to Chai Juin Hsien and Ru Jianghua for technical assistance. We also want to acknowledge the assistance given by Aw Yi Bing, Dr. Rajeev Singh, and Eng Chon Boon from NUH-NUS Tissue Repository, National University Hospital in supplying the fresh consented patient tissues. This work is supported by funding from the Academic Research Fund (AcRF) Tier 1 Faculty Research Committee (FRC) grant, National University of Singapore and from the grant NMRC/EDG/0058/2009, National Medical Research Council, Singapore.
Conflict of interest
There is no conflict of interest to be disclosed.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Assessment of tumorigenicity of primary cell cultures. (A) No colony was observed on soft agar of which primary culture cells were seeded (TC and NC). Colonies were observed on soft agar of HCT116 which is known to proliferate well without cellular matrices. (B) Average telomere length of primary culture cells (TC and NC). Legend: 1,3: Tumor; 2,4: Normal (PDF 146 kb)
About this article
Cite this article
Bellot, G.L., Tan, W.H., Tay, L.L. et al. Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients. J Cancer Res Clin Oncol 138, 463–482 (2012). https://doi.org/10.1007/s00432-011-1115-9
- Colorectal cancer
- Primary cultures
- Drug assays
- Drug resistance